Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial

por Giessen, C, Fischer von Weikersthal, L, Laubender, R P, Stintzing, S, Modest, D P, Schalhorn, A, Schulz, C, Heinemann, V
Publicado 2013

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative,...

por Perkhofer, L., Berger, A. W., Beutel, A. K., Gallmeier, E., Angermeier, S., Fischer von Weikersthal, L., Goetze, T. O., Muche, R., Seufferlein, T., Ettrich, T. J.
Publicado 2019

Sense of coherence and its context with demographics, psychological aspects, lifestyle, complementary and alternative medicine and lay aetiology

por Bargehr, B., Fischer von Weikersthal, L., Junghans, C., Zomorodbakhsch, B., Stoll, C., Prott, F.-J., Fuxius, S., Micke, O., Hübner, J., Büntzel, J., Hoppe, C.
Publicado 2023

Resilience in cancer patients and how it correlates with demographics, psychological factors, and lifestyle

por Festerling, Lara, Buentzel, J., Fischer von Weikersthal, L., Junghans, C., Zomorodbakhsch, B., Stoll, C., Prott, F.-J., Fuxius, S., Micke, O., Richter, A., Sallmann, D., Huebner, J., Hoppe, Catalina
Publicado 2022

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial

por Stintzing, S, Fischer von Weikersthal, L, Vehling-Kaiser, U, Stauch, M, Hass, H G, Dietzfelbinger, H, Oruzio, D, Klein, S, Zellmann, K, Decker, T, Schulze, M, Abenhardt, W, Puchtler, G, Kappauf, H, Mittermüller, J, Haberl, C, Giessen, C, Moosmann, N, Heinemann, V
Publicado 2011

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104

por Boeck, S, Jung, A, Laubender, R P, Neumann, J, Egg, R, Goritschan, C, Vehling-Kaiser, U, Winkelmann, C, Fischer von Weikersthal, L, Clemens, M R, Gauler, T C, Märten, A, Klein, S, Kojouharoff, G, Barner, M, Geissler, M, Greten, T F, Mansmann, U, Kirchner, T, Heinemann, V
Publicado 2013

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

por Stintzing, S, Wirapati, P, Lenz, H -J, Neureiter, D, Fischer von Weikersthal, L, Decker, T, Kiani, A, Kaiser, F, Al-Batran, S, Heintges, T, Lerchenmüller, C, Kahl, C, Seipelt, G, Kullmann, F, Moehler, M, Scheithauer, W, Held, S, Modest, D P, Jung, A, Kirchner, T, Aderka, D, Tejpar, S, Heinemann, V
Publicado 2019